Table 2 Distribution of centrally assessed tumor markers by FISH and IHC
N (%) | ||
|---|---|---|
FISH | CEP17 status (n = 1031) | |
Median (range) | 2.00 (0.70-26.55) | |
No gain | 620 (60.1) | |
Gain | 411 (39.9) | |
HER2 (gene copies) (n = 1031) | ||
Median (range) | 2.55 (0.70-45.15) | |
Low normal-replicated (≤4) | 742 (72.0) | |
Low gain (4–6) | 65 (6.3) | |
High gain (>6) | 224 (21.7) | |
HER2 gene status (n = 1031) | ||
Non-amplified1 | 787 (76.3) | |
Amplified2 | 244 (23.7) | |
TOP2A (gene copies) (n = 1031) | ||
Median (range) | 2.15 (0.70-26.15) | |
Low normal-replicated (≤4) | 875 (84.9) | |
Low gain (4–6) | 77 (7.5) | |
High gain (>6) | 79 (7.7) | |
TOP2A gene status (n = 1031) | ||
Deleted | 52 (5.0) | |
Non-amplified | 875 (84.9) | |
Amplified3 | 104 (10.1) | |
IHC | HER2 (n = 1014) | |
0 | 319 (31.5) | |
1+ | 379 (37.4) | |
2+ | 171 (16.9) | |
3+ | 145 (14.3) | |
TopoIIa (n = 953) | ||
Negative | 441 (46.3) | |
Positive | 512 (53.7) | |
ER (n = 1018) | ||
Negative | 272 (26.7) | |
Positive | 746 (73.3) | |
PgR (n = 1024) | ||
Negative | 335 (32.7) | |
Positive | 689 (67.3) | |
Ki67 (n = 1000) | ||
Low | 322 (32.2) | |
High | 678 (67.8) |